Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

Clinical and Experimental Metastasis

Volumn 30, Issue 7, 2013, Pages 867-876

  Birkeland, Einar ^a,b   Busch, Christian ^a,b,d   Berge, Elisabet Ognedal ^a,b   Geisler, Jürgen ^b,e,f   Jönsson, Göran ^c   Lillehaug, Johan Richard ^a   Knappskog, Stian ^a,b   Lønning, Per Eystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY   (Sweden)

^d Klinikk Bergen   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

BRAF; Chemoresistance; Dacarbazine; Melanoma; NRAS

Indexed keywords

B RAF KINASE; DACARBAZINE; N RAS PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOTHERAPY; ONCOGENE N RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SKIN METASTASIS; SUBCUTANEOUS METASTASIS; TISSUE SECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER;

EID: 84890429134     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9587-4     Document Type: Article

References (44)

1. Rigel DS (2008) Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 58(5 Suppl 2):S129-S132
2. Francken AB, Accortt NA, Shaw HM et al (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95(11):1401-1407
3. Eggermont AM (2006) Reaching first base in the treatment of metastatic melanoma. J Clin Oncol 24(29):4673-4674
4. Akslen LA, Angelini S, Straume O et al (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Investig Dermatol 125(2):312-317
5. Ugurel S, Thirumaran RK, Bloethner S et al (2007) B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2(2):e236
6. Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16(6):471-478
7. Albino AP, Nanus DM, Mentle IR et al (1989) Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4(11):1363-1374
8. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954
9. Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239-1246
10. Jakob JA, Bassett RL Jr, Ng CS et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-4023
11. Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855-867
12. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707-714
13. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-365
14. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114
15. Tanami H, Imoto I, Hirasawa A et al (2004) Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23(54):8796-8804
16. Jeuken J, van den Broecke C, Gijsen S et al (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114(2):121-133
17. Shi H, Moriceau G, Kong X et al (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
18. Seth R, Crook S, Ibrahem S et al (2009) Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the RAS/RAF signalling pathway in advanced colorectal cancer. Gut 58(9):1234-1241
19. Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387-390
20. Carninci P, Hayashizaki Y (1999) High-efficiency full-length cDNA cloning. Methods Enzymol 303:19-44
21. Lagonigro MS, De Cecco L, Carninci P et al (2004) CTAB-urea method purifies RNA from melanin for cDNA microarray analysis. Pigment Cell Res 17(3):312-315
22. Nozawa H, Yamamoto T, Uchihi R et al (1999) Purification of nuclear DNA from single hair shafts for DNA analysis in forensic sciences. Leg Med (Tokyo) 1(2):61-67
23. Busch C, Geisler J, Lillehaug JR et al (2010) MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 46(11):2127-2133
24. Wong CW, Fan YS, Chan TL et al (2005) BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 58(6):640-644
25. Jonsson G, Busch C, Knappskog S et al (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16(13):3356-3367
26. Cruz F III, Rubin BP, Wilson D et al (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63(18):5761-5766
27. Shinozaki M, Fujimoto A, Morton DL et al (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10(5):1753-1757
28. Willmore-Payne C, Holden JA, Tripp S et al (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36(5):486-493
29. Platz A, Egyhazi S, Ringborg U et al (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 1(4):395-405
30. Rubinstein JC, Sznol M, Pavlick AC et al (2010) Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 8:67
31. Menzies AM, Haydu LE, Visintin L et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242-3249
32. Colombino M, Capone M, Lissia A et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522-2529
33. Modrek B, Ge L, Pandita A et al (2009) Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 7(8):1244-1252
34. Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24):1878-1890
35. Jonsson G, Dahl C, Staaf J et al (2007) Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26(32):4738-4748
36. Rajakulendran T, Sahmi M, Lefrancois M et al (2009) A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461(7263):542-545
37. Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251-263
38. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516
39. Pavey S, Johansson P, Packer L et al (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23(23):4060-4067
40. Garnett MJ, Rana S, Paterson H et al (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20(6):963-969
41. Poulikakos PI, Zhang C, Bollag G et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287):427-430
42. Moreau S, Saiag P, Aegerter P et al (2012) Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 19(13):4314-4321
43. Mann GJ, Pupo GM, Campain AE et al (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Investig Dermatol 133(2):509-517
44. Lonning PE, Knappskog S, Staalesen V et al (2007) Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 18(8):1293-1306